65,437 trials
Anemia
Primary: Number of Participants With Anemia — 185; 172; 139; 191 participants — p=0.32
Glaucoma · Ocular Hypertension
Primary: Change of Intraocular Pressure (IOP) From Baseline to Week 8 — -2.59; -1.62 mmHg
Pneumococcal Infections
Primary: Concentration of Serotype-Specific IgG Antibodies — 15.26; 0.01; 3.1; 0.06 ug/ml
Allergic Conjunctivitis
Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532
Parkinson's Disease
Primary: Change in Pulse Rate (Supine, After 1 Minute) — 2.0 beats per minute
Community-Acquired Infections
Primary: Number of Patients by Clinical Response at Test-of-Cure (TOC) Visit. — 6; 2; 1 participants
Psoriatic Arthritis
Primary: Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis — 176; 119 participants
Aortic Stenosis
Primary: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) — 333; 355 Participants — p=0.591
Colonoscopy
Primary: Adenoma Detection — 63; 59 participants
Rheumatoid Arthritis
Primary: Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline — 170; 70 Participants — p=0.0195
Pneumococcal Infection
Primary: Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 3 — 0.6…
Cancer of Cervix
Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029
Chronic Kidney Disease, Stage 5 · Secondary Hyperparathyroidism
Primary: Calcium Absorption Fractions Analyzed by Analysis of Variance (ANOVA) — 0.103; 0.108 Fractions — p=0.573
HIV-1
Primary: Change From Baseline in Limb Fat at Week 48 — 392; -257 grams (g) — p=0.0014
Tumors
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 2 Participants